Skip to main content

US-FDA Warns that Hydroxychloroquine has Higher Mortality Rate

US Food and Drug Administration (US-FDA) Warning on Hydroxychloroquine Higher Mortality Rate

On April 24, the US Food and Drug Administration (US-FDA) issued a notice saying that hydroxychloroquine and chloroquine are undergoing clinical trials, and it has not been proven that these drugs can safely and effectively treat new coronary pneumonia.

Although clinical trials are underway to determine the safety and effectiveness of these drugs for COVID-19, the known side effects of these drugs should be considered.
FDA encourages healthcare professionals to carefully screen and monitor each patient’s decision to help mitigate these risks.

The FDA stated that medical personnel must be aware that these drugs may cause serious and potentially life-threatening heart rhythm problems.

In particular, the published medical literature and the National Toxic Data System of the American Association of Poison Control Centers involve serious heart-related adverse events and deaths in COVID-19 patients using hydroxychloroquine and chloroquine alone or in combination with the antibiotic azithromycin or other drugs.

Adverse Side Effects of  Hydroxychloroquine

These adverse events include abnormal heart rhythms, such as prolonged QT intervals, dangerous tachycardia (called ventricular tachycardia and ventricular fibrillation), and in some cases death. 

When patients with other heart diseases receive these drugs, the risk of these heart diseases may also increase.

Earlier, Trump tweeted on March 21 that the combination of hydroxychloroquine and azithromycin can treat new coronary pneumonia, and said this treatment has become "one of the biggest disruptive achievements in medical history."

On April 13th, Trump emphasized the possible clinical effect of hydroxychloroquine in a White House press release. 
The Associated Press once quoted US government officials as saying that Trump highly recommended hydroxychloroquine because he wanted to give the American people "hope."
Simulation of US-FDA Warning on Hydroxychloroquine Higher Mortality Rate in COVID-19 patients

According to Global News, the famous American vaccine expert Brett refused to use billions of dollars allocated by Congress for drugs lacking scientific value because he resisted the widespread use of hydroxychloroquine, and politics with the Trump administration’s leadership Conflict, and was recently fired.

Hydroxychloroquine has been approved for clinical trials

The Swiss Novartis company confirmed on April 20 that the company's hydroxychloroquine has been approved for clinical trials in the United States, and plans to recruit 440 new crown patients in more than 10 locations in the United States to strive to release the test results as soon as possible.

Hydroxychloroquine increases the mortality in the COVID-19 Treatment

Trump corrects himself that he is not a doctor.
Hydroxychloroquine is a 4-aminoquinoline derivative antimalarial drug. Its action and mechanism are similar to chloroquine, but its toxicity is only half of that of chloroquine. 

As the second-generation anti-malarial drug, it has always been the World Health Organization's preferred anti-malarial drug and the drug of choice for inhibiting lupus erythematosus syndrome.

Side Effects of Hydroxychloroquine on coronavirus patients

According to the report released by the FDA this time, patients with new coronary pneumonia will have serious side effects when using hydroxychloroquine. 

FDA Commissioner Stephen Hahn stated that medical staff are seeking every possible treatment option for patients, and we want to ensure that they are provided with the appropriate information needed to make the best medical decisions.

However, just as the FDA announced the news, a survey report by the US Veterans Health Administration came to a similar conclusion.

It is understood that the data of 368 hospitalized patients with new coronary pneumonia (all male, median age 65 years and over, mostly black) from March 9 to April 11, 2020 by the US Veterans Health Administration was reviewed Found during analysis.

The report showed that under standard conditions of care, the group of patients receiving hydroxychloroquine had the largest number of deaths, with a case fatality rate of 27.8%. 

What is the Mortality Rate of Hydroxychloroquine combined with Azithromycin?

The mortality rate of hydroxychloroquine combined with azithromycin group was 22.1%. 
More critically, in patients who did not take hydroxychloroquine, the mortality rate was 11.4%.

Based on the above data, the research scholars initially concluded that compared with the group of patients who did not receive hydroxychloroquine, the group using hydroxychloroquine had a higher risk of death from any cause.

Although research scholars admit that the research results have certain limitations in terms of patient enrollment, gender and age. But they also emphasized that hydroxychloroquine should be used with caution in hospitalized patients with new coronary pneumonia, especially not in combination with azithromycin.

The introduction of this research result also caused a 180 ° turn in Trump's attitude. 
According to information reported by, the President of Honduras just spoke with Trump, saying that the effect of hydroxychloroquine is very good. 
Trump said he was not a doctor. Trump believes that maybe it helps, if it helps, that's great. If it doesn't help, don't use it.

Hydroxychloroquine does have clinical side effects 

The efficacy of new coronary pneumonia is still inconclusive.

As early as March 2020, in the absence of any research evidence, Trump said on the social platform, "Hydroxychloroquine and azithromycin together will be a special drug to save patients and reverse the epidemic.

Subsequently, some well-known American media people, even the US Food and Drug Administration, began to respond to Trump's call to promote hydroxychloroquine. 
According to the CCTV news client, the US Fox News conducted more than 300 publicity campaigns on hydroxychloroquine in two weeks.

Trump's repeated Recommendation of Hydroxychloroquine

After Trump repeatedly recommended hydroxychloroquine, Novartis also responded and reached an agreement with the FDA to conduct a phase III clinical trial of hydroxychloroquine treatment in patients with new coronary pneumonia.

According to Novartis’ plan, this is a phase III clinical trial involving approximately 440 patients and will be conducted in dozens of research centers in the United States.

If the drug proves to be beneficial for the treatment of new coronary pneumonia, Novartis will donate up to 130 million doses of hydroxychloroquine through Sandoz to support global clinical treatment.

Hydroxychloroquine not yet fully tested in new coronavirus patients

In view of the fact that hydroxychloroquine has not been fully tested in patients with new coronary pneumonia, the medical community has not yet made any conclusions about the effectiveness of hydroxychloroquine in the treatment of new coronary pneumonia.

Up to now, a number of clinical tests have been carried out at home and abroad to apply hydroxychloroquine as a single drug or in combination with antibiotics to treat new coronavirus.

The latest and larger sample of research results released by the French team of Laourte on April 10 showed that the mortality rate of patients who received a combination of hydroxychloroquine and azithromycin for at least 3 days in the Masai Mediterranean Infectious Disease Hospital, The mortality rate of patients in all public hospitals in the Marseille region of France is significantly reduced.

On March 31, the results of the research team of the People’s Hospital of Wuhan University showed that 31 patients received standard treatment and received an additional 5 days of oral hydroxychloroquine treatment. 
The clinical recovery time and the cough relief time were both Significantly shorter than patients who received only standard treatment.

However, the above two research teams have stated that patients with new coronary pneumonia will have clinical side effects when taking hydroxychloroquine treatment.

In fact, hydroxychloroquine has been used for clinical treatment of malaria and rheumatoid arthritis since the date of approval. 

Anthony Fudge, director of the National Institute of Allergy and InfectiousDiseases under the National Institutes of Health, argues that more tests are needed to determine whether hydroxychloroquine can safely and effectively fight the new coronavirus.


Popular posts from this blog

Difference Between COVID-19 Coronavirus and Other Flu Epidemic Infections

What are the differences between COVID-19 and the flu epidemic?The epidemic caused by the new Coronavirus (2019-nCoV) is still spreading. This disease, which has just been officially named COVID-19, has caused more than 40,000 infections and more than 1,000 deaths. At the same time, on the other side of the ocean, another epidemic also attracted people's attention. The flu season in the United States is on schedule. 
According to data released by the US Centers for Disease Control and Prevention, as of February 1, 22 million to 31 million people are expected to be infected during the flu season, and the number of patients dying from influenza is between 12,000 and 30,000. 
Seeing such figures, some readers may be surprised when they think: Is the flu epidemic in the United States worse? What are the differences between COVID-19 and the flu epidemic? Is this really the case? What are the differences between COVID-19 and the flu epidemic?
The facts are being unraveled below: 1. Unknown ris…

FDA Launches New Website to Encourage COVID-19 Rehabilitation Patients to Donate Plasma

According to foreign media TechCrunch, one of the ways currently being sought to develop effective treatments for COVID-19 is to use convalescent plasma. Basically, this means using plasma from COVID-19 patients who have fully recovered, hoping to transfer the antibodies they produced during the fight against the virus to others. 

US Food and Drug Administration (FDA) creates dedicated website to seek recovery plasma donationsThe US Food and Drug Administration (FDA) has created a dedicated new website that seeks recovery plasma donations from COVID-19 rehabilitation patients and explains their potential uses.
The use of plasma during recovery is hardly a new concept. In fact, it has been used since the late 1890s and was used during the Spanish influenza pandemic in 1918, although "the results were mixed."
Modern methods can help improve the efficacy and potential of recovered plasma as a therapeutic method. There are currently some drugs under development that use plasma (ani…

Considerations Before Electrocardiogram ECG Test